CompletedNCT03926052
Lisdexamfetamine to Maintain Treatment for Binge Eating and Obesity
About this title
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment
Read the official source — NCT03926052Medication studyAges 18–64United StatesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: August 7, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 61
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT03926052
- Official title
Show the full official title
Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Did this study involve medication?
Yes. The study involved medication, including Lisdexamfetamine Dimesylate and Placebo.
Who was this study for?
Listed age limits: 18 years to 64 years.
